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ABSTRACT
Immune-mediated endocrine adverse events induced by nivolumab therapy are related to the activation of the 
immunological system, and often they affect the pituitary, thyroid, and pancreas leading to hypophysitis, thyroiditis, 
and diabetes mellitus. The exact pathomechanism of nivolumab-induced endocrinopathy usually remains unknown. 
The endocrine adverse events are unique when compared to other immune-mediated adverse events because 
the manifestations are often irreversible and require a life-long hormonal replacement and careful monitoring. 
Endocrinopathies in patients with disseminated neoplastic disease, often present with non-specific symptoms, 
making them difficult to diagnose. The cooperation of a clinical oncologist and endocrinologist is crucial for mak-
ing a correct diagnosis and for inducing appropriate hormone replacement therapy. This attitude may improve 
prognosis in oncological patients with endocrine complications of immunotherapy. In this article, we present the 
current data regarding the clinical management of immune-mediated endocrinopathies, including hypophysitis, 
thyroiditis, and diabetes mellitus. 
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Introduction
Hormonal disorders that occur during the im-
munotherapy of neoplasms with ‘immune checkpoint 
inhibitors’, also including nivolumab, are relevant to 
activation of the immunological system and usually 
involve such endocrine organs as: hypophysis, thyroid, 
and pancreas. The two major endocrinopathies observed 
during the immune checkpoint blockade are hypophysitis 
(typically induced by anty-CTLA-4 antibodies) and thy-
roiditis leading to thyrotoxicosis and/or hypothyroidism 
(induced by anti-PD-1, anti-PD-L1, and anti-CTLA-4 an-
tibodies). The incidence of other dysfunctions of the 
endocrine system, such as type I diabetes mellitus or 
primary adrenocortical gland insufficiency, is much 
lower. The adverse events concerning the endocrine 
system are unique compared to other immunological 
complications of the immunotherapy because they are 
usually irreversible. Immune-mediated endocrinopathies 
leading to the insufficiency of a given endocrine gland 
require a permanent hormonal substitution in affected 
patients [1]. The anti-PD-1 and anti-CTLA-4 antibodies 
induce similar immunological side effects, also concern-
ing the endocrine system. However, their incidence and 
intensity are usually less exacerbated after administration 
of anti-PD-1 antibodies [2, 3].
Correct functioning of the endocrine system is 
based on a precise functioning of the feedback loops 
between hypophysis and each peripheral endocrine 
gland. As well as the endocrine dysfunction, we also 
observe symptoms associated with the immunological 
inflammation of a given gland. A good example may 
be hypophysitis, which causes not only such symptoms 
as headaches or, less frequently, vision disturbances 
related to the compression by the enlarged gland of the 
optic chiasm, but also many symptoms associated with 
hypothyroidism, adrenal insufficiency, or sexual gland 
dysfunction. The symptoms of the endocrinopathies in 
patients with a disseminated neoplastic disease may be 
unspecific, which impedes the oncologist in making an 
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appropriate diagnosis [4, 5]. These symptoms may mimic 
progression of neoplastic disease. On the other hand, 
thyroiditis may be asymptomatic and detected during 
the routine hormonal tests. The symptoms of adrenal 
gland insufficiency are initially very discrete and mostly 
manifest as weakness, tiredness, nausea, headaches, 
and hypotension.
Endocrinopathies associated with nivolumab therapy 
are usually observed during the initial weeks of immu-
notherapy. In clinical trials with nivolumab, the median 
time to the onset of endocrinopathies was: 1.5 months 
for hyperthyroidism, 2.9 months for hypothyroidism, 
4.9 months for hypophysitis, and 4.4 months for diabetes 
mellitus type 1 [6]. However, we should not forget that 
the occurrence of these complications may be delayed. 
The endocrinopathies may also occur after the termi-
nation of the nivolumab therapy. That is why patients 
should be carefully monitored for several months after 
completion of therapy [4, 5].
This paper refers to the characteristics and manage-
ment of the most common endocrinopathies associated 
with nivolumab administration. 
Hypophysitis
Incidence
Hypophysitis is a typical endocrinopathy occurring 
during the administration of the anti-CTLA-4 (ipili-
mumab) antibodies. Its incidence is variable (0–17%) 
[7, 8]. The differences in the incidence of hypophysitis 
may result from different doses of ipilimumab, absence 
of unified schedules of the hormonal control tests, and 
with a diverse clinical awareness of the occurrence of 
symptoms of the impaired function of hypophysis. In 
a recent report the incidence of hypophysitis equalled 
10–15% [9]. Improved awareness of oncologists prob-
ably results in more frequent diagnosis of hypophysitis 
[9]. The impairment of hypophysis during the anti-CT-
-LA-4 antibody therapy is independent of the type of 
neoplasm. However, male sex and older patient’s age 
are considered risk factors for developing hypophysi-
tis. On the contrary, a primary lymphocytic hypophysitis 
is more frequent in young females, in reproductive age, 
and often after child delivery [10, 11]. Hypophysitis in 
patients treated with nivolumab is significantly less 
frequent (< 1%) [9]. 
In clinical trials evaluating nivolumab in mono-
therapy, hypophysitis occurred in 0.6% of patients, and 
the median time to appearance of symptoms equalled 
4.9 months, whereas in patients treated with a combi-
nation of nivolumab and ipilimumab this affliction was 
observed more frequently — in 9% of patients, on aver-
age after 2.7 months of immunotherapy [6].
Pathogenesis
The majority of cases of ipilimumab-induced hy-
pophysitis may result from the ectopic expression of 
CTLA-4 antigens on the cells of a human hypophysis, 
which may be targeted by the anti-CTLA-4 antibodies 
[12, 13]. However, the mechanism of nivolumab-induced 
hypophysitis remains undiscovered. 
Symptoms and diagnosis
The symptoms of hypophysitis are relatively unspe-
cific, wherefore an oncologist may have difficulties in 
making an appropriate diagnosis. The most common 
symptoms include: headache, tiredness, nausea, reduced 
appetite, weight loss, cold intolerance, vertigo, and vi-
sion disturbances [9, 11, 14]. These symptoms may be 
overlooked or attributed to a potential progression of 
the neoplastic disease. The diagnosis of immune check-
point inhibitor-induced hypophysitis is mostly based 
on the presence of clinical symptoms, hypopituitarism 
in hormonal tests, and of a typical magnetic resonance 
image (MRI) of the pituitary gland (a symmetric en-
largement of the pituitary with usually homogenous 
enhancement post-intravenous contrast administration) 
after initiating the immunotherapy. During the acute 
phase of the inflammation the image of the hypophysis 
is abnormal in 75% of patients while in the other 25% 
it may be unchanged [4, 5, 9, 10]. An MRI of the central 
nervous system (CNS) should also be done in order to 
exclude the metastases to the brain. However, we must 
remember that performing a MRI of a CNS should not 
defer the hormonal diagnostics and the initiation of the 
hormonal replacement therapy.
Management
Anti-PD-1 and anti-CTLA-4 antibody-induced hy-
pophysitis mostly leads to a combined anterior pituitary 
hormone deficiency. An insufficiency of the posterior 
lobe occurs extremely rarely and manifests as diabetes 
insipidus [4, 5, 9, 10]. Administration of high doses of 
glucocorticosteroids (GCS) is controversial because it 
does not lead to the resolution of the hypopituitarism. 
It is recommended that a physiological substitution be 
started with hydrocortisone and high doses of gluco-
corticosteroids (e.g. prednisone 1 mg per kg of body 
weight per day) should be limited only to situations when 
a so-called ‘mass effect’ is observed as a strong headache 
or vision disturbances (Figure 1) [4, 5]. 
In a patient with suspicion of hypophysitis, first 
ACTH deficiency should be excluded, which leads to 
a secondary insufficiency of the adrenal gland. The 
initial symptoms may be discrete and unspecific. The 
most common symptoms include: weakness, tiredness, 
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loss of appetite, weight loss, concentration disorders, 
nausea, vomiting, abdominal pains, low blood pressure 
with orthostatic hypotension, and headaches. In case 
of suspicion of adrenal insufficiency we should test the 
morning concentration of cortisol (at 8 a.m.) and eventu-
ally of ACTH. A low concentration of cortisol (< 5 μg/L) 
associated with low or normal level of ACTH suggests 
a secondary insufficiency of the adrenal gland induced 
by hypophysitis. Administration of substitutional doses 
of hydrocortisone (20–30 mg per day orally) leads to 
prompt clinical improvement, which also confirms the 
hypophysitis. We should remember that hypophysitis 
associated with severe adrenal insufficiency (low blood 
pressure, dehydration, hyponatraemia, hyperkaliaemia) 
is equivalent to an adrenal crisis and is a life-threatening 
condition. Such patients require immediate hospitali-
sation and urgent intravenous administration of high 
doses of GCS (hydrocortisone 50–100 mg intravenously 
every six hours) together with appropriate intravenous 
hydration and further extended endocrine diagnostics 
(Figure 1). It is crucial to differentiate an adrenal crisis 
from a septic crisis, so it is recommended that a.o. blood 
cultures are taken.
L-thyroxin substitution of a secondary hypothy-
roidism should be implemented in cases of decreased 
FT4 concentration below the minimum reference 
level and after normalisation of the adrenal func-
tion. L-thyroxin is recommended at an initial dose of 
25–50 μg administered during fasting, in the morning. 
The FT4 level should be controlled in further monitoring 
and L-thyroxin dose adjustment, unlike the TSH level 
in primary hypothyroidism. 
The serum levels of gonadotropins (FSH and LH), 
as well as of oestradiol and testosterone in women and 
men respectively, should be evaluated in patients with 
diagnosed hypophysitis. Hormonal replacement therapy 
of hypogonadism should include testosterone adminis-
tration in men and oestrogens in premenopausal women, 
and it should be concordant with current recommenda-
tions of the endocrine societies. 
Nivolumab therapy may be continued once the 
symptoms subside and a hormonal rebalance of a hy-
popituitarism is achieved [4, 5].
Thyroiditis
Incidence
During the process of activation of T lymphocytes 
against neoplastic antigens the immune checkpoint block-
ade may initiate an attack on the thyroid cells. Thyroid 
disorders occurring during the nivolumab therapy are the 
most frequent among endocrinopathies, and its diagnosis 
rate increases [4, 5]. In the clinical trials the hypothyroid-
ism secondary to the thyroiditis occurred in 9% of pa-
tients receiving nivolumab monotherapy (averagely after 
2.9 months after the start of the therapy), on the other 
hand, hyperthyroidism was observed in 2.7% of patients 
on nivolumab, on average after 1.5 months of therapy, and 
in a population treated with a combination of nivolumab 
and ipilimumab hypothyroidism was detected in 22% and 
hyperthyroidism in 8% of patients [6]. 
Pathogenesis
The relationship between the induction (by an-
ti-PD-1 antibodies) of the autoimmune processes in the 
thyroid gland is still unclear. In the study by Orlov et 
al. [2] classical features of silent, painless thyroiditis, 
which manifested as a temporary thyrotoxicosis, were 
observed in 60% of patients whereas in the other 40% 
a hypothyroid phase was documented. In patients with 
thyrotoxicosis the antibodies against the TSH receptor 
(also present in Graves-Basedow disease) were negative 
whereas 67% of patients had anti-TPO and anti-TG 
antibodies. These antibodies were positive in all patients 
in whom hypothyroidism was diagnosed from the begin-
ning of therapy [2].
Symptoms and diagnosis
Painless thyroiditis is typically present and is 
manifested by temporary thyrotoxicosis (low TSH level, 
elevated concentrations of FT4 and FT3) [2, 15, 16]. 
Thyrotoxicosis may have an asymptomatic course or 
induce such symptoms as: palpitations, weight loss, 
tiredness, and excessive sweating. A hyperthyroid phase 
of thyrotoxicosis resolves into euthyroidism or more 
often into hypothyroidism. In some patients immuno-
therapy-induced thyroid gland disorder is right from the 
beginning, manifesting with symptoms of hypothyroid-
ism: tiredness, obstructions, cold intolerance, weight 
gain, hair loss, and hear rate deceleration. 
During the acute phase of silent thyroiditis an in-
creased metabolism of 18-fluorodeoxyglucose may be 
detected by PET-CT imaging within the thyroid gland 
[16]. In such cases an iodine uptake evaluation test of 
the thyroid gland will detect an inhibited uptake of 
131I. Unfortunately, scintigraphy of the thyroid in onco-
logical patients is rarely authoritative due to frequently 
performed control CT exams with use of iodine-based 
contrast [4, 5].
Management
Routine evaluation of thyroid gland functions is 
recommended before and after administration of the 
first and each consecutive dose of nivolumab. It is 
also advisable to test for the presence of anti-thyroid 
299
Maria Stelmachowska-Banaś, Wojciech Zgliczyński, The management of nivolumab-induced endocrine immune-related adverse events
antibodies, especially in cases of abnormal TSH 
levels (Figure 1). The acute phase of thyroiditis as-
sociated with thyrotoxicosis is usually asymptomatic 
and does not require any therapy, only monitoring of 
the TSH, FT4, and FT3 levels [17]. In symptomatic 
cases, especially in the case of tachycardia, it is recom-
mended that a beta-adrenolytic drug is started (e.g. 
propranolol 3 × 40 mg orally). In the rare cases of 
severe hyperthyroidism, it is necessary to administer 
glucocorticosteroids (e.g. prednisone 1 mg/kg of body 
weight). The literature includes a casuistic report of 
a thyroid crisis induced by combined therapy with 
nivolumab and ipilimumab in a patient with a dis-
seminated stage of melanoma. This patient required 
therapy with a beta-adrenolytic drug, thyreostatics, 
and systemic administration of GCS, which resulted in 
clinical improvement and normalisation of the thyroid 
hormone levels [18].
We should also remember that a decreased level 
of TSH in a patient receiving immunotherapy may 
result from the administration of high doses of gluco-
corticosteroids used to control other immune-related 
adverse events or neoplastic metastases to the brain. 
A low TSH level combined with decreased FT4 level 
may suggest secondary hypothyroidism in the course 
of hypophysitis. This suspicion always requires exclu-
sion of insufficiency of the adrenal gland and evalua-
tion of the morning levels of cortisol and eventually 
of ACTH before starting L-thyroxine substitution. 
In the case of primary hypothyroidism, a substitu-
tion therapy with an L-thyroxine should be started at 
a dose of 25–50 μg administered during fasting and 
in the morning. The dose of L-thyroxine should be 
adjusted every 4–6 weeks so that the TSH level could 
reach the normal reference value. A full substitutional 
dose of L-thyroxine usually equals 1.6 μg/per kg of body 
weight per day. 
In cases of subclinical hypothyroidism and of 
rightly corrected hypothyroidism immunotherapy with 
nivolumab may be continued.
Diabetes mellitus type 1
Incidence
Autoimmunological type 1 diabetes mellitus is a rare 
complication of nivolumab therapy. There are very few 
case reports accessible in the medical literature [19–22]. 
In clinical trials with use of nivolumab, diabetes mel-
litus was diagnosed in 0.9% of patients, on average 
4.4 months after beginning immunotherapy. Among 
patients treated with combination of nivolumab and 
ipilimumab diabetes mellitus was observed more fre-
quently — in 1.5% of patients, on average 2.5 months 
after the start of therapy [6].
Pathogenesis
Type 1 diabetes mellitus is caused by destruction 
of the beta cells of the pancreas by T autoreactive 
lymphocytes. Nivolumab-induced diabetes mellitus is 
primarily insulin-dependent and has a fulminant course, 
as well as having no remission phases, unlike typical 
autoimmune type 1 diabetes mellitus. In these rapidly 
progressing cases of hyperglycaemia no autoantibodies 
to islet cells may be detected; however, in some patients 
markers of both cellular and humoral activation of the 
immune system have been identified (e.g. presence of 
the anti-glutamine acid decarboxylase antibodies) [19]. 
Moreover, it was stated that same HLA haplotypes 
predispose to the development of nivolumab-induced 
diabetes mellitus [23]. However, further studies are nec-
essary in order to confirm the pathogenetic mechanism 
of this endocrinopathy.
Symptoms and diagnosis
A rapid increase in the glucose level with total defi-
ciency of insulin secretion, confirmed by undetectable 
serum levels of peptide C at diagnosis, is a character-
istic feature of anti-PD-1 antibody-induced diabetes 
mellitus. Some cases of ketone acidosis were reported 
as a primary symptom of nivolumab-induced diabetes 
mellitus [19]. Oncologists must consider that this com-
plication may occur and should routinely monitor serum 
glucose levels during the immunotherapy (Figure 1). 
It is important to educated patients about the possi-
ble symptoms of development of ketone acidosis e.g.: 
polyuria, polydipsia, dehydration, nausea, emesis, 
diarrhoea, and abdominal pain, which may constitute 
a direct danger to life. Fulminant type I diabetes mellitus 
is characterised by ketone acidosis and a rapid course, 
which results in deterioration of the patient’s health 
in a few days or weeks and results from the complete 
inhibition of insulin secretion. This subtype of diabetes 
has also been described during nivolumab therapy [21, 
23]. The diagnostic criteria of the fulminant diabetes 
include a rapid onset of hyperglycaemia with ketone 
acidosis and a normal level of glycated haemoglobin 
(HbA1c) despite high serum glycaemia and undetectable 
concentration of peptide C.
It is important to differentiate between the frequent 
gastrointestinal symptoms associated with nivolumab 
therapy resulting from e.g. enterocolitis and gastroin-
testinal symptoms in the course of ketone acidosis in the 
fulminant form of type 1 diabetes mellitus. 
Management
Undiagnosed fulminant diabetes mellitus is a fatal 
condition. Therapy should be started immediately in 
each case of type 1 diabetes [22]. Therapy involves typ-
300
OncOlOgy in clinical practice 2017, Vol. 13, No. 6
ical management of ketone acidosis with a continuous 
intravenous insulin-therapy, intravenous hydration, and 
frequent monitoring of laboratory parameters in order 
to rebalance the anion gap and electrolytes imbalance. 
Once the patient’s clinical state is improved and acidosis 
has been resolved a multiple-dose, subcutaneous insulin 
injection model may be implemented.  Cooperation of 
both the oncologist and endocrinologist is crucial in 
order to coordinate education of a patient and to plan 
appropriate ambulatory control. Further management of 
the diabetes mellitus should by individualised with con-
sideration of the nutritional status of a given patient and 
of his/her general prognosis for overall survival [19–21].
In the case of a good control of diabetes, therapy 
with nivolumab may be continued [19–22].
Summary 
1. In the case of suspicion of hypophysitis, evaluation 
of morning concentration of cortisol is crucial. A low 
cortisol level confirms a diagnosis of a secondary 
adrenal insufficiency. This condition requires im-
mediate implementation of hydrocortisone supple-
mentation.
2. Hyperthyroidism associated with nivolumab immu-
notherapy is mostly temporary and does not require 
use of thyreostatics, only observation or use of be-
ta-adrenolytic drugs. 
3. In cases of occurrence of hypothyroidism, it is 
recommended that substitution with L-thyroxine 
preparation be implemented.
4. Cooperation between the oncologist and the 
endocrinologist is crucial in the management of 
patients with immunotherapy-induced endocrinopa-
thies. Making an appropriate diagnosis of hormonal 
disorders and adequate hormonal substitution may 
improve the prognosis of oncological patients in 
whom immunotherapy-induced endocrinopathies 
have occurred.
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